ArticleWorld journal of gastroenterology2015
MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.Cells · 2026Review
- MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- LINC01012 upregulation promotes cervical cancer proliferation and migration via downregulation of CDKN2D.Oncology letters · 2023Article
- MicroRNA-203a-3p may prevent the development of thyroid papillary carcinoma via repressing MAP3K1 and activating autophagy.Journal of clinical laboratory analysis · 2022Article
- Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients.Scientific reports · 2021Article
- Article
- Micro-RNA-451 Reduces Proliferation of B-CPAP Human Papillary Thyroid Cancer Cells by Downregulating Expression of Activating Transcription Factor 2.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Downregulation of METTL7B Inhibits Proliferation of Human Clear Cell Renal Cancer CellsFrontiers in oncology · 2021Article
- Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis.Cancer medicine · 2020Article
- miR-203 affects esophageal cancer cell proliferation, apoptosis and invasion by targeting MAP3K1.Oncology letters · 2020Article
- Alterations of cell cycle genes in cancer: unmasking the role of cancer stem cells.Molecular biology reports · 2020Review
- Association Study ofPharmacogenomics and personalized medicine · 2020Article
- Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.World journal of gastroenterology · 2019Article
- Reduced microRNA-451 expression in eutopic endometrium contributes to the pathogenesis of endometriosis.World journal of clinical cases · 2019Article
- miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer.OncoTargets and therapy · 2019Review
- Tumor suppressor activity of miR-451: Identification of CARF as a new target.Scientific reports · 2018Article
- Article
- Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles.Cell & bioscience · 2018Article
- Serum miR-451a Levels Are Significantly Elevated in Women With Endometriosis and Recapitulated in Baboons ( Papio anubis) With Experimentally-Induced Disease.Reproductive sciences (Thousand Oaks, Calif.) · 2017Article
- Comprehensive miRNA expression profiles in the ilea of Lawsonia intracellularis-infected pigs.The Journal of veterinary medical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the underlying molecular mechanisms of miR-451 to inhibit proliferation of esophageal carcinoma cell line EC9706.
methodsAssays for cell growth, apoptosis and invasion were used to evaluate the effects of miR-451 expression on EC cells. Luciferase reporter and Western blot assays were used to test whether cyclin-dependent kinase inhibitor 2D (CDKN2D) and MAP3K1 act as major targets of miR-451.
resultsThe results showed that CDKN2D and MAP3K1 are direct targets of miR-451. CDKN2D and MAP3K1 overexpression reversed the effect of miR-451. MiR-451 inhibited the proliferation of EC9706 by targeting CDKN2D and MAP3K1.
conclusionThese findings suggest that miR-451 might be a novel prognostic biomarker and a potential target for the treatment of esophageal squamous cell carcinoma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.